Enitociclib, formerly known as VIP152, is a well-tolerated and clinically active CDK9 inhibitor that has led to durable complete metabolic remission (CR) in 2 of 7 patients with DH-DLBCL treated once weekly with 30 mg enitociclib by intravenous infusions (27, 28). The gene discussed is CDK9; the disease is diffuse large B-cell lymphoma.